Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Sadia Khan: Insights from US Training in Oncoplastic Breast-Conserving Surgery丨2026 Beijing Breast Cancer Forum

    The 2026 Beijing Breast Cancer Forum and Beijing Breast Reconstruction Forum was held in Beijing from June 23 to 28, 2026. The meeting brought together leading breast surgery experts from China and abroad to discuss advances in breast cancer diagnosis and treatment, breast reconstruction, and oncoplastic breast-conserving surgery. As part of the “International Perspectives ·…

    2026.08.14
  • 2026 Northern Breast Cancer Forum丨Prof. Xueli Mo: From Single-Target Therapy to the ADC Era — Tracing the Evolution of HER2-Positive Advanced Breast Cancer

    From trastuzumab opening the door to HER2-targeted therapy, to dual-targeted regimens becoming the cornerstone of first-line treatment, and now to ADCs reshaping survival outcomes, the treatment history of HER2-positive advanced breast cancer reflects the continuous evolution of precision oncology. The 2026 Northern Breast Cancer Forum was successfully held in Qingdao from July 25 to 26.…

    2026.08.14
  • 2026 Northern Breast Cancer Forum丨Prof. Yunjiang Liu: From Endocrine Therapy to Precision Targeted Therapy — Milestones in HR-Positive Breast Cancer

    Hormone receptor (HR)-positive breast cancer accounts for approximately 70% of all breast cancer cases. From the early exploration of ovarian ablation more than a century ago, to tamoxifen ushering in the era of endocrine therapy, and then to CDK4/6 inhibitor-based combinations reshaping the treatment landscape of advanced disease, each major therapeutic breakthrough has profoundly altered…

    2026.08.14
  • First Global Guideline for the Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine Published

    Recently, the China Association of Chinese Medicine (CACM) Group Standard, Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine was officially released in Beijing. As the world’s first guiding standard for the integrated evaluation of evidence on the efficacy of traditional Chinese medicine (TCM), the standard was jointly developed under the leadership of…

    2026.08.13
  • EHA 2026 | Prof. Stephen Ansell & Dr. Zhihui Li: Decoding the Future of Hodgkin Lymphoma

    How has PD-1 blockade transformed the treatment of Hodgkin lymphoma? Can biomarkers such as CD30 and 9p24.1 amplification further refine precision therapy? And what lessons can HL teach us about the future of T-cell lymphoma? At EHA 2026, Dr. Zhihui Li of Beijing Gaobo BoRen Hospital joined Prof. Stephen Ansell of Mayo Clinic for an…

    2026.08.12
  • EHA 2026丨Prof. Stephen Ansell and Dr. Zhihui Li: Exploring the Immunobiology and Precision Treatment of Hodgkin Lymphoma

    Crossing borders, exchanging insights, and exploring the frontiers of hematology. During the 2026 Congress of the European Hematology Association (EHA), Oncology Frontier – Hematology Frontier invited Dr. Zhihui Li, Director of Beijing Gaobo BoRen Hospital, and Prof. Stephen Ansell of Mayo Clinic for an in-depth discussion on the tumor immune microenvironment and precision treatment of…

    2026.08.10
  • Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

    The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as…

    2026.08.06
  • Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

    The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology,…

    2026.08.06
«previous next»
Recent Posts
  • Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
  • Professor Haixia Fu: Balancing the Need to Increase Platelet Counts and the Risk of Thrombosis in ITP Patients | 2026 China-France Scientific Symposium on Hematology and Immunology
  • 2026 CSCO China–International Dialogue | Professor Kai-Keen Shiu analyzes breakthrough strategies for immunotherapy in MSS/pMMR colorectal cancer
  • Professor Aibin Liang: Enhancing CAR-T Therapy with the A2AR-Targeting Natural Product TAIII—From CAR-Treg Mechanisms to Clinical Translation | 2026 China-France Scientific Symposium on Hematology and Immunology
  • China and France Join Forces to Advance Hematology and Immunology: The 2026 China-France Scientific Symposium on Hematology and Immunology Held in Beijing
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top